Poor Sanofi. Their "blockbuster in waiting" Acomplia (rimonabant) is not yet launched and already they have to settle a legal battle over the use of its name.
The settlement came after the Electronic Frontier Foundation (a leading civil liberties organization working to protect rights in the digital world) filed suit on behalf of the AcompliaReport.com, an independent online newsletter devoted to reporting about Acomplia, which may help people lose weight and quit smoking, but is not yet approved by the FDA.
"Sanofi's tactics threatened to quash free and accurate speech," said EFF staff attorney Corynne McSherry. "The website uses the Acomplia mark solely to refer to Sanofi's product. That use is a textbook fair use. And basic First Amendment principles barred Sanofi from using trademark law to shut down an independent news site."
Regarding the product. Insider reserves judgement but saw this page on the AcompliaReport.com website:
http://www.acompliareport.com/News/news-110705.htm
No comments:
Post a Comment